格隆汇12月1日丨众生药业(002317.SZ)在投资者互动平台表示，公司全资子公司先强药业拥有的NMN （β-烟酰胺单核苷酸）按化工原料进行生产和销售。 ...

Core Viewpoint - The company has confirmed that its wholly-owned subsidiary, Xianqiang Pharmaceutical, produces and sells NMN (β-nicotinamide mononucleotide) as a chemical raw material, in response to investor inquiries about the development of longevity drugs [1] Group 1 - The company is engaged in the production and sale of NMN [1] - NMN is identified as a chemical raw material [1]

Investment Rating - The report does not explicitly state an investment rating for the industry [2] Core Views - The pharmaceutical and biotechnology sector saw a weekly increase of 2.67%, underperforming the Wind All A index (2.9%) but outperforming the CSI 300 index (1.64%). The raw material drug sector experienced a decline of 4.27%, while chemical preparations and pharmaceutical circulation products increased by 4.18% and 3.71%, respectively [3][8] - Recent policies in Shanghai and Beijing aim to support the high-quality development of the medical device industry, indicating a shift towards innovation and global competitiveness in this sector. The report suggests monitoring the transformation progress of leading companies in the medical device field [3][12] - Flu activity is on the rise, with the percentage of flu-like cases reported by sentinel hospitals in southern provinces reaching 7.8%, up from 6.8% the previous week, and higher than the same period in 2022 and 2024 [3][11] Summary by Sections Market Weekly Review - The pharmaceutical and biotechnology sector increased by 2.67% from November 24 to November 28, 2025, with raw material drugs declining by 4.27% and chemical preparations increasing by 4.18% [8][9] - Individual stock performances included significant gains for Haiwang Biological (38.2%), Yue Wannianqing (36.2%), and Guangji Pharmaceutical (31.7%), while *ST Changyao (-15.3%), Huitai Medical (-9.6%), and Kangwei Century (-8.8%) saw notable declines [11] Industry News and Key Company Announcements Important Industry Events - The report highlights the increase in flu-like illness percentages in both southern (7.8%) and northern (8.6%) provinces, indicating a significant rise in flu activity compared to previous years [11][12] Industry News - Significant approvals were noted, including the NMPA's approval of Xinmeiyue® for treating moderate to severe plaque psoriasis and the FDA's accelerated approval of Sibeprenlimab for IgAN treatment [12][14] Company Announcements - Notable announcements include the FDA approval of a generic injectable drug by Jianyou Co. and the successful completion of a Phase III trial for JS001sc, a subcutaneous PD-1 monoclonal antibody for non-small cell lung cancer [15][16]

Core Viewpoint - The current flu season in China is marked by a significant increase in drug demand due to a larger infected population, with a competitive landscape emerging as multiple domestic innovative flu drugs are launched, challenging traditional imported and older medications [2][17]. Group 1: Flu Season Trends - The flu season is peaking in northern China while southern regions are still rising, with a national flu positivity rate exceeding 40% [5][6]. - Increased flu cases are particularly noted among children, with hospitals reporting a significant rise in infections [7][5]. - Experts predict that some provinces may reach flu peak by mid-December, with a nationwide decline expected by early January [6]. Group 2: Rise of Domestic Flu Medications - The market for flu medications is becoming increasingly diverse, with various approved treatments available, including neuraminidase inhibitors and RNA polymerase inhibitors [9][8]. - 2025 is referred to as the "Year of Domestic Flu New Drugs," with several innovative flu medications launched this year, intensifying market competition [9][8]. - New drugs like Isodaz (Mashurashave) and Anruwei (Anglave) have been approved, representing significant advancements in flu treatment [10][9]. Group 3: Market Dynamics and Pricing - The price of new RNA polymerase inhibitors is comparable to imported drugs, with significant sales growth observed for both classic and innovative flu medications [12][11]. - Sales data indicates a substantial increase in demand for flu medications, with Oseltamivir sales reaching 5.9 billion yuan in 2024, marking a 237% increase in recent weeks [14][12]. - The competitive landscape is shifting, with traditional flu drugs losing their competitive edge post-collective procurement, emphasizing the need for innovative high-quality drugs [18][17]. Group 4: Investment and Market Outlook - The flu medication market in China is projected to grow at a compound annual growth rate of 20.2%, potentially reaching 26.9 billion yuan by 2028 [18][17]. - Companies are responding to rising stock prices in the flu drug sector, with some developing new generation neuraminidase inhibitors and focusing on innovative drug development [18][17]. - The influx of domestic companies into the flu drug market is driven by the market's high certainty and relatively safe research environment [19][17]. Group 5: Challenges and Recommendations - The influx of similar products raises concerns about market saturation and price wars, prompting calls for diversified and personalized flu vaccine products [20][19]. - There is a notable gap in pediatric flu medications, despite children having a significantly higher infection rate compared to adults [20][19]. - E-commerce platforms are enhancing their flu product offerings, indicating a strong potential for growth in online sales channels for flu medications [20][19].

Core Insights - The flu season is currently peaking, with a significant increase in infection rates leading to a surge in medication demand. Unlike previous years, the market is now seeing a competition between imported drugs and a variety of newly launched domestic innovative flu medications [1][5][12] - The market for flu medications is projected to grow significantly, with an expected compound annual growth rate of 20.2% from 2024 to 2028, potentially reaching a market size of 26.9 billion yuan by 2028 [12] Market Dynamics - The flu medication market is experiencing a "new vs. old" battle, as multiple new domestic drugs enter the market, challenging the dominance of traditional medications like oseltamivir, which has seen its price drop to under 2 yuan per pill due to collective procurement [1][9] - The introduction of new antiviral drugs, such as RNA polymerase inhibitors, is changing the treatment landscape, with some new drugs priced similarly to imported options, thus increasing competition [8][10] Product Launches - Several innovative flu medications have been approved for clinical use in China, including: - Isodaz (Mashurashave tablets) by Qingfeng Pharmaceutical, targeting influenza A and B [7] - Anruwei (Angladi tablets) by Zhongsheng Pharmaceutical, the first global PB2 protein inhibitor for flu treatment [7] - Jikeshou (Maseilashave tablets) by Zhengxiang Pharmaceutical, another RNA polymerase inhibitor [7] - The first year of sales for these new drugs has shown significant growth, with Mabalosave achieving 630 million yuan in sales, marking an 800% increase [10] Consumer Behavior - There is a notable increase in the sales of flu medications, with oseltamivir's sales volume rising by 237% in a week, while new drugs like Mabalosave also saw an increase of 180% [8][10] - Despite the high price of new medications, awareness and adoption among consumers remain low, with less than 5% of those aware of their flu diagnosis opting for the new generation of drugs [10] Competitive Landscape - The influx of domestic pharmaceutical companies into the flu medication market is driven by the high certainty of market demand and relatively safe R&D prospects [13] - However, this has led to concerns about product homogeneity and potential price wars, as many companies pursue similar targets in drug development [13] Future Outlook - The flu medication market is expected to continue evolving, with ongoing innovations and potential price reductions as more products enter the market and negotiations for inclusion in national insurance schemes progress [11][12]

Core Viewpoint - On November 28, the Shanghai Composite Index rose by 0.34%, the Shenzhen Component Index increased by 0.85%, and the ChiNext Index went up by 0.7%. The most significant net inflow of funds was into Aerospace Development (000547.SZ), amounting to 392 million yuan, while the largest net outflow was from Zhongsheng Pharmaceutical (002317.SZ), totaling 277 million yuan [1][3]. Group 1: Stock Performance - Aerospace Development saw a closing price increase of 10.02% with a turnover rate of 25.76% and a net buying amount of 392.34 million yuan, accounting for 7.59% of the total trading volume [3][4]. - Zhongsheng Pharmaceutical experienced a closing price drop of 10% with a turnover rate of 18.78% and a net selling amount of 276.59 million yuan, representing 7.84% of the total trading volume [4][10]. Group 2: Institutional Activity - A total of 25 stocks appeared on the trading leaderboard, with institutions participating in 18 stocks, resulting in a net buying amount of 505 million yuan [4][5]. - The stock with the highest institutional net buying was New Jin Road (000510.SZ), which closed up by 5.65% and had a turnover rate of 39.07% [5][6]. Group 3: Northbound Capital - Northbound capital participated in 18 stocks, with a total net outflow of 93.56 million yuan, where the most significant net buying was in Aerospace Development, amounting to 92.68 million yuan [10][13]. - The stock with the highest net selling by northbound capital was Shida Group (600734.SH), with a net outflow of 102 million yuan, closing down by 8.3% [10][14]. Group 4: Divergence in Institutional and Northbound Capital - There was a divergence in the trading of certain stocks, such as Haiwang Biological, where institutions sold 22.34 million yuan while northbound capital bought 442.09 million yuan [13][14]. - In the case of Wanrun New Energy, institutions net bought 32.63 million yuan, while northbound capital net sold 51.75 million yuan [13][14].

11月28日，沪指上涨0.34%，深成指上涨0.85%，创业板指上涨0.70%，沪深300指数上涨0.25%。可交易 A股中，上涨的有4122只，占比75.87%，下跌的1193只。 资金面上，今日主力资金全天净流入108.40亿元。其中，创业板主力资金净流入4.67亿元；科创板主力 资金净流入3.20亿元；沪深300成份股主力资金净流出13.82亿元。 分行业来看，申万所属的一级行业中，今日上涨的有29个，涨幅居前的行业为钢铁、农林牧渔，涨幅为 1.59%、1.59%。跌幅居前的行业为银行、煤炭，跌幅为0.83%、0.14%。 今日各行业资金流向 | 行业 | 日涨跌幅（%） | 资金流向（亿元） | 行业 | 日涨跌幅（%） | 资金流向（亿元） | | --- | --- | --- | --- | --- | --- | | 电子 | 1.30 | 34.23 | 社会服务 | 0.88 | 0.62 | | 有色金属 | 1.44 | 30.51 | 公用事业 | 0.31 | 0.54 | | 汽车 | 1.21 | 23.03 | 煤炭 | -0.14 | 0.09 | | 电力设备 | 1.3 ...

证券代码：002317 编号：2025-013 广东众生药业股份有限公司投资者关系活动记录表 | | √ □特定对象调研 □分析师会议 | | --- | --- | | | □媒体采访 □业绩说明会 | | 投资者关系活动 类别 | □新闻发布会 □路演活动 | | | □现场参观 □一对一沟通 | | | □其他（ ） 平安证券股份有限公司、长城证券股份有限公司、东莞证券股 | | | 份有限公司、易米基金管理有限公司、东莞市私募基金业协 会、秋水高通私募基金管理（上海）有限公司、深圳市麻王投 资集团有限公司、盛世恒瑞（广东）投资有限公司、深圳市明 | | | 华信德私募证券基金管理有限公司、南通熙宁投资管理有限 | | | 公司、国城资本有限公司、广州中科粤创孵化器投资管理有限 | | | 公司、深圳市梦工场投资管理有限公司、广州明玥私募证券投 | | 参与单位及人员 | 资基金管理有限公司、东莞市哥们私募证券投资基金管理有 | | | 限公司、广东众帮投资有限公司、东莞市鼎和私募证券投资管 | | | 理有限公司、广西世安医疗科技有限公司、衣食住行私募证券 | | | 投资管理（广东）有限公司、东莞市 ...

Group 1 - The vitamin sector experienced a decline of 0.39%, ranking among the top losers in the concept sector, with companies like Zhongsheng Pharmaceutical and Guangji Pharmaceutical hitting the daily limit down [1][2] - Notable gainers in the vitamin sector included Haiwang Biological, *ST Zhongji, and Zhenhua Co., which rose by 10.03%, 5.01%, and 4.99% respectively [1][4] - The vitamin sector saw a net outflow of 706 million yuan from major funds, with 43 stocks experiencing net outflows, and 10 stocks seeing outflows exceeding 10 million yuan [2][3] Group 2 - The top net outflow stock was Zhongsheng Pharmaceutical, with a net outflow of 684 million yuan, followed by Xinhua Pharmaceutical and Guangji Pharmaceutical with net outflows of 58.33 million yuan and 50.49 million yuan respectively [2][3] - Conversely, the stocks with the highest net inflow included Haiwang Biological, Zhenhua Co., and Xinhecheng, with net inflows of 145 million yuan, 67.37 million yuan, and 24.76 million yuan respectively [2][4] - The trading volume for Zhongsheng Pharmaceutical was notably high, with a turnover rate of 18.78% despite a price drop of 10% [3][4]

Market Overview - On November 28, A-shares saw a collective rise in the three major indices, with the Shanghai Composite Index up 0.34% to 3888 points, the Shenzhen Component Index up 0.85%, and the ChiNext Index up 0.7% [1] - Over 4100 stocks in the market experienced gains, with market hotspots focusing on titanium dioxide, Hainan, satellite internet, and commercial aerospace sectors, while traditional Chinese medicine stocks declined and flu-related stocks corrected [1] Key Stocks - Guosheng Technology (603778) rose by 9.96%, marking its 10th consecutive trading day of gains, driven by solid-state batteries and photovoltaic technology [2] - Dream Home (603216) increased by 10.02%, with its stock price rising due to the termination of acquisition plans and chip concepts [2] - Jinfu Technology (003018) saw a 10.03% rise, planning to acquire Lanyuan Technology [2] - Aerospace Development (002413) surged by 10.06%, benefiting from commercial aerospace and radar technology [2] - The top net buying stocks on the day included Aerospace Development, Dongtian Micro (301183), and LeiKe Defense (002413), with net purchases of 3.92 billion, 2.13 billion, and 2.05 billion respectively [2][4] Sector Performance - The commercial aerospace sector showed strong performance, with Aerospace Development achieving a 10.02% increase and a trading volume of 51.71 billion [4][10] - The military industry sector faced declines, with stocks like Jianglong Shipbuilding dropping over 10% and Aerospace Development hitting the daily limit [10] - The semiconductor and technology sectors also saw significant movements, with stocks like Dongtian Micro and Qian Zhao Optoelectronics experiencing gains of 20% and 20.01% respectively [10][15] Trading Dynamics - The top net selling stocks included Zhongsheng Pharmaceutical, Te Yi Pharmaceutical, and Xinhua Du, with net sales of 2.77 billion, 1.90 billion, and 1.53 billion respectively [5][6] - The trading volume and turnover rates for several stocks were notably high, with some stocks like Dongtian Micro and Qian Zhao Optoelectronics achieving turnover rates of 29.00% and 15.60% respectively [6][15] - The market showed a mix of strong buying interest in certain sectors while facing selling pressure in others, indicating a diverse trading environment [6][10]